Scientific reports

Using selective activators of KIR and NKG2A to help natural killer cells avoid attacking healthy cells missing normal markers

Updated

Abstract

Introducing selective inhibitory KIR agonists allows HLA class I-deficient iPSCs to evade immune rejection by NK cells.

  • HLA class I-deficient iPSCs are susceptible to rejection by natural killer (NK) cells due to the .
  • Chimeric HLA-E protein suppresses NK cell rejection mediated by the inhibitory receptor , but does not address NKG2A-negative NK cells.
  • Novel agonists for inhibitory (KIRs) were developed to enhance immune tolerance.
  • Selective agonists for KIR2DL1, KIR2DL2/3, and KIR3DL1 were found to enable HLA class I-deficient iPSCs to evade NK cell rejection.
  • An NKG2A-selective agonist was identified as an alternative that activates the NKG2C receptor, further promoting immune tolerance.

Simplified

Key figures

Fig. 1
NK cell populations, receptor expression, and against in various NK cell types
Highlights reduced killing activity in exposed to alleles and shows receptor expression patterns relevant to immune response.
41598_2025_18394_Fig1_HTML
  • Panel A
    Gating strategy for isolating NK cells from using SSC-FSC, live cell marker , and CD3/CD56 markers, followed by detection of and expression
  • Panel B
    Distribution of NK cell populations expressing combinations of NKG2A and KIR2DL2/3/S2 receptors across 20 samples, shown as percentage of total NK cells
  • Panel C
    histograms showing NKG2A expression on , PBMC-derived NK cells from two donors (A and B), and NKG2A-sorted PBMC-derived NK cells, with sorted cells visibly enriched for NKG2A
  • Panel D
    Killing activity of NK-92 and PBMC-derived NK cells (including NKG2A-sorted) against K562 cells with or without HLA-E alleles after 6 hours co-culture; killing activity is reduced in presence of HLA-E0101 and HLA-E0103 alleles
Fig. 2
Effects of and anti- antibodies on NK-92 cell against
Highlights contrasting cytotoxic responses of with inhibitory versus activating to HLA-C and anti-KIR antibodies.
41598_2025_18394_Fig2_HTML
  • Panels A and B
    Killing activity of expressing KIR2DL2 or KIR2DL3 against K562 cells with various HLA-C types or treated with anti-KIR antibody; NK-92 cells with inhibitory KIR show reduced killing, while those with activating KIR show increased killing; killing activity is lower with HLA-C*0302 and anti-KIR antibody treatment.
  • Panel C
    Schematic of membrane-bound anti-KIR antibody single-chain variable fragment () fused with firefly luciferase for detection in cytotoxicity assays.
  • Panel D
    Killing activity of NK-92 cells expressing KIR2DL2 against K562 cells expressing membrane-bound anti-KIR scFv or controls; killing activity appears reduced with K562 cells expressing anti-KIR scFv compared to controls.
  • Panel E
    Killing activity of NK-92 cells expressing activating KIR alleles (KIR2DS1, KIR2DS2, KIR2DS4) against K562 cells expressing membrane-bound anti-KIR scFv; killing activity appears increased with KIR2DS1-expressing NK-92 cells compared to controls.
Fig. 3
Selective agonists reduce NK cell killing of T cells and without activating other .
Highlights selective KIR2DL2/3 agonist’s ability to reduce NK cell killing of T cells and iPSCs, enhancing immune tolerance.
41598_2025_18394_Fig3_HTML
  • Panel A
    Binding affinity of KIR2DL2, KIR2DL3, KIR2DS1, KIR2DS2, and KIR2DS4 to *0302 and anti- antibodies on , shown by normalized mean fluorescent intensity.
  • Panel B
    Killing activity of expressing KIR2DL2, KIR2DL3, KIR2DS1, KIR2DS2, or KIR2DS4 against K562 cells with different ; visibly reduces killing activity compared to controls.
  • Panel C
    Killing activity of -derived against PBMC-derived T cells with different KIR genotypes; KIR2DL2/3 agonist 61 significantly lowers T-cell killing in PBMC-E (C2/C2) but not in PBMC-C (C1/C1).
  • Panel D
    Killing activity of PBMC-derived NK cells against wild-type and iPSCs; KIR2DL2/3 agonist 61 significantly reduces killing of B2M knockout iPSCs.
Fig. 4
Structure and sequence details of binding to KIR2DL2.
Highlights the specific binding site of KIR2DL2/3 agonist 61 and its distinction from other .
41598_2025_18394_Fig4_HTML
  • Panel A
    Ribbon diagram of KIR2DL2/3 agonist 61 bound to KIR2DL2, with KIR2DL2 in green, Fab light chain in orange, and Fab heavy chain in cyan.
  • Panel B
    Amino acid sequence alignment of KIR family members showing differences from KIR2DL2 in red and highlighting epitopes of lirilumab (green boxes), Pan2D (blue boxes), and KIR2DL2/3 agonist 61 (yellow boxes).
1 / 4

Full Text

What this is

  • This research addresses immune rejection in allogeneic cell therapies, particularly in induced pluripotent stem cell (iPSC) applications.
  • Natural killer (NK) cells can reject HLA class I-deficient cells, a phenomenon known as the .
  • The study develops selective agonists for inhibitory receptors on NK cells, specifically () and , to enhance immune tolerance.

Essence

  • Selective agonists for and on NK cells effectively suppress immune rejection of HLA class I-deficient iPSCs, enhancing their therapeutic potential.

Key takeaways

  • Selective agonists for (KIR2DL1, KIR2DL2/3, KIR3DL1) were developed to suppress NK cell cytotoxicity. These agonists effectively protected HLA class I-deficient iPSCs from NK cell-mediated rejection.
  • The -selective agonist was identified as an alternative to chimeric HLA-E, providing additional immune tolerance by stimulating the activating receptor NKG2C without activating -expressing NK cells.
  • Combining KIR agonists with agonists demonstrated additive effects in suppressing NK cell activity, suggesting a comprehensive approach to evade immune rejection in therapeutic applications.

Caveats

  • The study primarily focuses on in vitro findings, which may not fully translate to in vivo efficacy in human applications. Further research is needed to validate these results in clinical settings.
  • The potential for off-target effects or unintended activation of other NK cell receptors remains a concern, necessitating careful evaluation of the safety profiles of these agonists.

Definitions

  • Killer immunoglobulin receptors (KIRs): A family of receptors on NK cells that recognize HLA class I molecules and modulate NK cell activity.
  • Missing-self response: An immune response where NK cells recognize and attack cells lacking self-HLA class I molecules.
  • NKG2A: An inhibitory receptor on NK cells that binds to HLA-E, suppressing NK cell activation.

Simplified

Funding

Competing interests

Declarations. Competing interests: SH, YK, YN, TK, SY, MN, TM and SU are employees of Daiichi Sankyo Co., Ltd. SH, YK, YN, TK, SY, MN and SU are inventors on a patent and patent application WO2024090458A1, entitled “Method for avoiding immune rejection using agonist for inhibitory KIR” that covers KIR agonist to evade immune rejection by NK cells. No funding other than from Daiichi Sankyo Co., Ltd. was obtained for this study. Other authors declare no conflict of interest.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free